CAS 13721-39-6|Sodium orthovanadate|3-oxo-3-(sodiooxy)-2,4-dioxa-3-vanada-1,5-disodapentane|3-oxo-3-(sodiooxy)-2,4-dioxa-3-vanada-1,5-disodapentane

General Information

Structure

Molecular Formula

Na₃O₄V

Molecular Mass

183.90841

Exact Mass

183.89292582

Charge

InChI

InChI=1S/3Na.4O.V

InChIKey

HQHUIUQMQXUPHI-UHFFFAOYSA-N

Canonic Smiles

[Na]O[V](=O)(O[Na])O[Na]

Isomeric Smiles

O([Na])[V](=O)(O[Na])O[Na]

Calculated Properties

JChem

H Acceptors

H Donor

LogD (pH = 5.5)

1.0622

LogD (pH = 7.4)

1.0622

Log P

1.0622

Molar Refractivity

5.4935

Polarizability

12.07504

Polar Surface Area

44.76

Rotatable Bonds

Lipinski's Rule of Five

true

Data Source

Commercial Catalog

Academic Data

Data Source

Names and Identifiers

IUPAC Traditional name

3-oxo-3-(sodiooxy)-2,4-dioxa-3-vanada-1,5-disodapentane

IUPAC name

3-oxo-3-(sodiooxy)-2,4-dioxa-3-vanada-1,5-disodapentane

Synonyms

Sodium orthovanadate

Names and Identifiers

Registration numbers

CAS Number

13721-39-6

PubChem CID

454045

PubChem SID

162037755

Registration numbers

Properties

Safety Information

Storage Condition

-20°C

Product Information

Salt Data

Sodium Salt

Properties

Related Proteins

No Data Available

Click here to submit data

Molecular Spectra

No Data Available

Click here to submit data

Molecule Details

Selleck Chemicals

S2000

Research Area

Description

Cancer

Biological Activity

Description

Sodium orthovanadate is an alkaline phosphatase and (Na,K)-ATPase inhibitor with IC50 of 10 μM.

Targets

Phosphatase

IC₅₀

10 μM ^[1]

In Vitro

In transient forebrain ischemia, Sodium orthovanadate rescues cells from delayed neuronal death in the hippocampal CA1 region. The neuroprotective effects of Sodium orthovanadate and IGF-1 are associated with preventing decreased Akt-Ser-473 phosphorylation in the CA1 region observed immediately after reperfusion. Akt is moderately activated in the cell bodies and dendrites of pyramidal neurons after orthovanadate treatment. The Sodium orthovanadate treatment also prevents the decrease in phosphorylation of mitogen-activated protein kinase (MAPK). ^[3] Sodium orthovanadate inhibits ASK1 through the PI3-K/Akt-dependent pathway. ^[4] Sodium orthovanadate up-regulates Akt activity in the brain and in turn rescue neurons from delayed neuronal death by inhibiting FKHR-dependent or -independent death signals in neurons. ^[4]

In Vivo

In a rat model of myocardial ischemic infarction, sodium orthovanadate rescues cells from ischemia/reperfusion injuries. Post-treatment with Sodium orthovanadate reduces infarct size in a dose-dependent manner. ^[5] Sodium orthovanadate treatment also ameliorates contractile dysfunction of the left ventricle 72 hours after reperfusion. The cytoprotective action of Sodium orthovanadate treatment is closely associated with inhibition of fodrin breakdown. Sodium orthovanadate treatment inhibits caspase-3 activation induced by ischemia. ^[6]

Clinical Trials

Features

Protocol

Kinase Assay ^[2]

ATPase assay

The coupled assay linking ADP production to NADH oxidation is used for all ATPase assays. The fraction of active enzyme is determined by measuring enzyme activity after linearity has been achieved by the activity prior to addition of Sodium orthovanadate. Final steady state hydrolysis rates are independent of the order addition of Sodium orthovanadate and enzyme.